Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Up 5.67%
As of Wednesday, September 02, Pyxis Oncology, Inc.’s PYXS share price has surged by 5.67%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Up 7.10%
As of Tuesday, September 01, Pyxis Oncology, Inc.’s PYXS share price has surged by 7.10%, which has investors questioning if this is right time to sell.Michael Rose
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 5.84%
As of Monday, August 24, Pyxis Oncology, Inc.’s PYXS share price has dipped by 5.84%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Up 8.01%
As of Friday, August 21, Pyxis Oncology, Inc.’s PYXS share price has surged by 8.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Up 9.70%
As of Wednesday, August 19, Pyxis Oncology, Inc.’s PYXS share price has surged by 9.70%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $297.3 | $289.2 | 31% |
|
| Shares Out (Mil) | 64.0 | 54.1 | 53% |
|
| Institutional Ownership | 75.3% | 93.1% | 45% |
|
| Float (Mil) | 49.6 | 42.2 | 47% |
|
| Beta | 1.32 | 0.94 | 76% |
|
| Avg Daily Volume (000s) | 579 | 451 | 62% |
|
| Price Change (52-week) |
142.5% | 59.8% | 95% |
|
| Growth | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (44.1%) | (10.1%) | 8% |
|
| EPS (5yr) | 36.5% | 15.9% | 86 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 63.8% | (15.6%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.278) | ($1.220) | ($1.128) | |
| Month Ago EPS | ($0.277) | ($1.223) | ($1.201) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.279) | ($1.229) | ($1.227) | |
| Year/Year Chg | (29.8%) | (4.8%) | (14.2%) | |
| Financials | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($89) | ($43) | 12% |
|
| EPS (TTM) | ($1.403) | ($1.500) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($68) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $2 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | $234 | $190 | 27% |
|
| Valuation | PYXS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 19.81 | 2.84 | 96% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.4% | 66.9% | 88% |
|
| Net Margin | (803.8%) | (74.2%) | 0% |
|
| ROA | (99.6%) | (47.8%) | 6% |
|
| ROE | (179.1%) | (55.0%) | 5% |
|
| Liabilities to Assets | 79.2% | 29.7% | 74% |
|
| F-Score | 1 | 3 | 1% |
|
Pyxis Oncology, Inc. did not pass any screens on 9/3/2026.
